3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia, Myeloid, Acute
12
Myelodysplastic Syndromes
8
Leukemia
8
Myeloproliferative Disorders
6
Lymphoma, Non-Hodgkin
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Recurrence
5
Primary Myelofibrosis
5
Lymphoma, T-Cell
5
Lymphoma
5
Hodgkin Disease
5
Multiple Myeloma
4
Graft vs Host Disease
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Follicular
3
Leukemia, Prolymphocytic, T-Cell
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Accelerated Phase
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Interventions
tofacitinib
7
ofatumumab
4
ibrutinib
4
Rituximab
2
KW-2478
2
Dasatinib
2
Alemtuzumab
2
ziconotide
1
sodium luminolate
1
ruxolitinib
1
oblimersen
1
obinutuzumab
1
mocetinostat
1
milatuzumab
1
ixekizumab
1
fludarabine
1
fenebrutinib
1
baricitinib
1
abexinostat
1
Saline Solution
1
Lenalidomide
1
Hsp90 inhibitor KU757
1
Etanercept
1
Cyclophosphamide
1
Bortezomib
1
B3(Fv)-PE38KDEL recombinant immunotoxin
1
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bronchiolitis Obliterans Syndrome
×
ruxolitinib
×
Lymphoid
×
Clear all
NCT03774082
2025-12-11
REACH 5
Novartis
Phase 2
Completed
46 enrolled
21 charts